SEI Investments’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107K | Sell |
76,629
-377,134
| -83% | -$616K | ﹤0.01% | 3172 |
|
|
2026
Q1 | $767K | Buy |
453,763
+377,134
| +492% | +$670K | ﹤0.01% | 2481 |
|
|
2025
Q4 | $109K | Buy |
+76,629
| New | +$112K | ﹤0.01% | 3001 |
|
|
2024
Q4 | – | Sell |
-342,427
| Closed | -$356K | – | 2736 |
|
|
2024
Q3 | $356K | Sell |
342,427
-12,965
| -4% | -$17.8K | ﹤0.01% | 2293 |
|
|
2024
Q2 | $615K | Sell |
355,392
-1,586
| -0.4% | -$3.19K | ﹤0.01% | 2086 |
|
|
2024
Q1 | $853K | Sell |
356,978
-8,444
| -2% | -$20.8K | ﹤0.01% | 1941 |
|
|
2023
Q4 | $1.22M | Sell |
365,422
-473,695
| -56% | -$1.27M | ﹤0.01% | 1807 |
|
|
2023
Q3 | $3.14M | Sell |
839,117
-12,548
| -1% | -$58K | 0.01% | 1382 |
|
|
2023
Q2 | $3.64M | Buy |
851,665
+115,146
| +16% | +$679K | 0.01% | 1353 |
|
|
2023
Q1 | $5.04M | Buy |
736,519
+59,001
| +9% | +$458K | 0.01% | 1183 |
|
|
2022
Q4 | $5.37M | Buy |
677,518
+14,558
| +2% | +$112K | 0.01% | 1021 |
|
|
2022
Q3 | $6.37M | Buy |
662,960
+873
| +0.1% | +$8.83K | 0.01% | 981 |
|
|
2022
Q2 | $4.79M | Buy |
662,087
+35,993
| +6% | +$313K | 0.01% | 1115 |
|
|
2022
Q1 | $8.08M | Buy |
626,094
+88,162
| +16% | +$1.12M | 0.02% | 861 |
|
|
2021
Q4 | $8.59M | Buy |
537,932
+193,917
| +56% | +$3.39M | 0.02% | 873 |
|
|
2021
Q3 | $5.53M | Sell |
344,015
-14,972
| -4% | -$219K | 0.01% | 1028 |
|
|
2021
Q2 | $4.96M | Sell |
358,987
-562
| -0.2% | -$7.96K | 0.01% | 1078 |
|
|
2021
Q1 | $5.25M | Buy |
359,549
+45,440
| +14% | +$771K | 0.01% | 991 |
|
|
2020
Q4 | $5.46M | Buy |
314,109
+108,329
| +53% | +$1.93M | 0.01% | 933 |
|
|
2020
Q3 | $3.77M | Buy |
205,780
+96,528
| +88% | +$1.8M | 0.01% | 1002 |
|
|
2020
Q2 | $1.95M | Buy |
109,252
+90,310
| +477% | +$1.53M | 0.01% | 1276 |
|
|
2020
Q1 | $311K | Sell |
18,942
-7,516
| -28% | -$139K | ﹤0.01% | 1921 |
|
|
2019
Q4 | $477K | Sell |
26,458
-7,116
| -21% | -$131K | ﹤0.01% | 1951 |
|
|
2019
Q3 | $684K | Sell |
33,574
-12,870
| -28% | -$257K | ﹤0.01% | 1743 |
|
|
2019
Q2 | $1.03M | Buy |
+46,444
| New | +$807K | ﹤0.01% | 1594 |
|
|
2018
Q1 | – | Sell |
-38
| Closed | – | – | 3483 |
|
|
2017
Q4 | $0 | Hold |
38
| – | – | ﹤0.01% | 3347 |
|
|
2017
Q3 | $1K | Buy |
+38
| New | +$503 | ﹤0.01% | 3047 |
|
|
2015
Q4 | – | Sell |
-9,773
| Closed | -$196K | – | 2536 |
|
|
2015
Q3 | $196K | Buy |
+9,773
| New | +$297K | ﹤0.01% | 1611 |
|
Other funds holding CHRS
TGY2IT
SB
KKRC
CM
CWG
SEI Investments's CHRS Position: Q2 2026 in Review
SEI Investments reduced its Coherus Oncology (CHRS) stake by 83% in Q2 2026, selling an estimated $616K and leaving 76,629 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3172.
SEI Investments first reported a position in CHRS in Q3 2015 and has held it in 28 quarters since. The position peaked at $8.59M in Q4 2021. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.
- SEI Investments held 76,629 shares of Coherus Oncology worth $107K as of Q2 2026.
- SEI Investments sold 377,134 Coherus Oncology shares in Q2 2026, an estimated $616K.
- Coherus Oncology made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3172 holding.
- SEI Investments first reported a position in Coherus Oncology in Q3 2015 and has held it in 28 quarters since.
- SEI Investments's Coherus Oncology position peaked at $8.59M in Q4 2021.
- 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.
Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.